Cencora Inc.
Cencora Announces $1.5 Billion Term Loan for Retina Consultants Acquisition
Summary
On November 26, 2024, Cencora, Inc. entered into a Term Credit Agreement providing a senior unsecured term facility of $1.5 billion to fund a portion of the cash consideration for the proposed acquisition of Retina Consultants of America. The Term Loan matures three years from the Closing Date. Additionally, Cencora obtained a $1.0 billion senior unsecured revolving credit facility. Both facilities are subject to customary conditions, including the consummation of the Acquisition.
Profitelligence Alerts
Get alerts for COR
Be first to know when Cencora Inc. files with the SEC.
Filing Categories
Exhibits (2)
Advertisement
About Cencora Inc.
Cencora Inc., formerly known as AmerisourceBergen Corporation, represents a pivotal entity in the global healthcare distribution and services sector. As a leading pharmaceutical sourcing and distribution services company, Cencora Inc. plays a critical role in ensuring the efficient supply of pharmaceutical products to a range of healthcare providers, including hospitals, pharmacies, and clinics. Its business model is centered on the seamless integration of logistics, consulting services, and the provision of innovative solutions aimed at improving pharmaceutical supply chain operations. Cencora Inc. impacts various segments of the healthcare industry by enhancing the availability and accessibility of healthcare products. Known for its global reach and extensive network of distribution centers, the company supports the delivery of critical medications and healthcare products across numerous geographies. Cencora Inc.'s significance in the market is underscored by its ability to partner with pharmaceutical manufacturers and healthcare providers to streamline processes, reduce costs, and improve patient outcomes. Headquartered in Conshohocken, Pennsylvania, Cencora Inc. remains a cornerstone of the healthcare distribution market, focusing on sustainability, innovation, and strategic collaborations.
Official SEC Documents
Advertisement